Investigation and prediction on resistance of infantile hemangioma in midanaphase of propranolol treatment

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16009281

Enrollment

Unknown

Registered

2016-09-27

Start date

2016-10-12

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infantile hemangioma

Interventions

midanaphase propranolol-resistance:local injection of propranolol

non-propranolol-resistance:termination of treatment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Aged from 1 month old to 12 months old; 2. Multifocal IH; 3. Segmental IH (PHACE syndrome was excluded); 4. Localized IH (diameter longer than 5 cm); 5. Widespread superficial IH; 6. Ulcerating IH or high risk of ulceration (necks/axilla/joints); 7. Breast IH in girls; 8. IH with higher functional risks including ear/labial/eyelid/nose/perineal lesions; 9. Airways or subglottic IH (MRI shows no more than 50% of airway obstruction); 10. IH of parotid gland.

Exclusion criteria

Exclusion criteria: 1. Life-threatening symptoms (progressive expiratory dyspnea, cardiac distress, etc.); 2. Visceral/digestive/intracranial IH; 3. Infant bronchial asthma or family history of asthma; 4. History of respiratory distress; 5. Heart block; 6. Bradycardia; 7. Severe cardiac anomalies; 8. Dysfunctions of the liver and kidneys; 9. Received previous therapies followed by propranolol treatment; 10. Unwillingness to sign a consent form.

Design outcomes

Primary

Measure	Time frame
the rate of residual lesion;	—

Countries

China

Contacts

Public ContactLei Chang

Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University, School of Medicine

changleiray@126.com+86 15921044093

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026